share_log

GRI Bio | 10-Q: Q2 2024 Earnings Report

GRI Bio | 10-Q: Q2 2024 Earnings Report

GRI Bio | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/15 00:39

Moomoo AI 已提取核心信息

GRI Bio reported financial results for Q2 2024, with a net loss of $2.25 million compared to $6.75 million in Q2 2023. Research and development expenses remained stable at $0.9 million, while general and administrative expenses decreased to $1.4 million from $5.1 million year-over-year. The company ended the quarter with $6.4 million in cash and cash equivalents.The company made significant progress in its clinical programs, particularly with GRI-0621 for idiopathic pulmonary fibrosis (IPF). Patient enrollment continues in the Phase 2a biomarker study, with interim data expected in Q4 2024 and topline results in Q1 2025. Additionally, GRI Bio received UK regulatory approval to expand the IPF trial internationally.During Q2, GRI Bio strengthened its financial position through multiple equity offerings, including a $4.4 million public offering in February and a $3.2 million offering in June 2024. The company also established an At-The-Market facility and regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements. Management believes current cash will fund operations into Q1 2025.
GRI Bio reported financial results for Q2 2024, with a net loss of $2.25 million compared to $6.75 million in Q2 2023. Research and development expenses remained stable at $0.9 million, while general and administrative expenses decreased to $1.4 million from $5.1 million year-over-year. The company ended the quarter with $6.4 million in cash and cash equivalents.The company made significant progress in its clinical programs, particularly with GRI-0621 for idiopathic pulmonary fibrosis (IPF). Patient enrollment continues in the Phase 2a biomarker study, with interim data expected in Q4 2024 and topline results in Q1 2025. Additionally, GRI Bio received UK regulatory approval to expand the IPF trial internationally.During Q2, GRI Bio strengthened its financial position through multiple equity offerings, including a $4.4 million public offering in February and a $3.2 million offering in June 2024. The company also established an At-The-Market facility and regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements. Management believes current cash will fund operations into Q1 2025.
GRI Bio公布了2024年第二季度的财务业绩，净亏损为225万美元，较2023年第二季度的675万美元有所减少。研发支出保持稳定，为90万美元，而一般管理费用则从去年的510万美元降至140万美元。公司在本季度末拥有现金及现金等价物640万美元。公司在其临床项目上取得了显著进展，特别是用于特发性肺纤维化（IPF）的GRI-0621。患者入组仍在进行中，预计将在2024年第四季度获得中期数据，2025年第一季度获得顶线结果。此外，GRI Bio获得了英国监管机构的批准，以在国际上扩大IPF试验。在第二季度，GRI Bio通过多次股权发行增强了其财务状况，包括在2024年2月进行的440万美元的公开发行和6月的320万美元的发行。公司还建立了市场交易设施，并恢复了符合纳斯达克的最低买盘价格和股东权益要求。管理层相信，当前的现金将支持运营直到2025年第一季度。
GRI Bio公布了2024年第二季度的财务业绩，净亏损为225万美元，较2023年第二季度的675万美元有所减少。研发支出保持稳定，为90万美元，而一般管理费用则从去年的510万美元降至140万美元。公司在本季度末拥有现金及现金等价物640万美元。公司在其临床项目上取得了显著进展，特别是用于特发性肺纤维化（IPF）的GRI-0621。患者入组仍在进行中，预计将在2024年第四季度获得中期数据，2025年第一季度获得顶线结果。此外，GRI Bio获得了英国监管机构的批准，以在国际上扩大IPF试验。在第二季度，GRI Bio通过多次股权发行增强了其财务状况，包括在2024年2月进行的440万美元的公开发行和6月的320万美元的发行。公司还建立了市场交易设施，并恢复了符合纳斯达克的最低买盘价格和股东权益要求。管理层相信，当前的现金将支持运营直到2025年第一季度。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日